Purpose of review Active investigation suggests immune checkpoint inhibitor therapy and therapeutic cancer vaccines provide clinical benefit for genitourinary malignancies including prostate cancer, renal cell carcinoma, and bladder cancer. Recent developments in the utility of immune checkpoint inhibitor and vaccine therapy for the management of genitourinary malignancies are highlighted in this review.
INTRODUCTION
Immunotherapy's emergence in the treatment of cancer is having a revolutionary impact on the therapeutic landscape for many diseases. Genitourinary (GU) malignancies are among those benefiting from these new therapeutic options. Immune checkpoint inhibitors in bladder and kidney cancer and therapeutic cancer vaccines in prostate cancer are providing evidence that immune-based treatments may substantially prolong survival for patients with GU malignancies.
Immune homeostasis is maintained in part by receptors that act as checkpoints that modulate immune cell activity [1] . We are now able to manipulate these checkpoints to achieve antitumor immune responses. Cytotoxic T lymphocyteassociated antigen 4 (CTLA-4) was the first recognized target in the rapidly expanding field of immune checkpoint inhibition. CTLA-4 is a regulator of effector T cell and regulatory T cell (T reg ) function that binds antigen-presenting cellexpressed B7 receptors (CD80/CD86) and interrupts costimulatory signaling, partially via SHP-2 phosphatase recruitment [2] [3] [4] .
Ipilimumab (Yervoy; Bristol-Myers Squibb, Princeton, New Jersey, USA) is a fully humanized mAb targeting CTLA-4. It was approved by the US Food and Drug Administration (FDA) in 2011 for the treatment of advanced melanoma after phase III studies showed improvement in overall survival (OS) [5, 6, 7] . Along with OS benefit, a small proportion of patients treated with ipilimumab achieve long-term survival [8, 9] . Given the success of ipilimumab in treating melanoma, interest has developed in expanding the use of anti-CTLA-4 therapy to a range of malignancies, including those of genitourinary origin.
Signaling through another checkpoint, programmed cell death protein 1 (PD-1) binding to its ligand PD-L1, is associated with diminished T-cell function. In this review, we discuss the therapeutic implications of immune checkpoint blockade and therapeutic vaccines in the management of genitourinary malignancies, evaluate available clinical trial data, and discuss active trials awaiting completion.
PROSTATE CANCER
Although immune checkpoint inhibitors have yet to demonstrate clinical benefit in prostate cancer, the therapeutic cancer vaccine sipuleucel-T demonstrated an ability to extend OS in patients with metastatic castration-resistant prostate cancer (mCRPC) in a randomized phase III trial (25.8 vs. 21.7 months for placebo; hazard ratio [HR] ¼ 0.78; P ¼ 0.03) [10] . A subsequent analysis has suggested that patients in the control arm of this study who were later given cryopreserved immune cells as part of a planned crossover may have performed better clinically than would have been expected [11] . Therefore, the results of the phase III trial may have underestimated the actual therapeutic benefit of sipuleucel-T. Another therapeutic cancer vaccine in development is PSA-TRICOM (Prostvac, developed by the US National Cancer Institute, licensed to BN Immunotherapeutics, Mountain View, California, USA), a poxviral-based vaccine targeting prostate-specific antigen (PSA), that has demonstrated an OS advantage in a randomized phase II study and has completed accrual to a phase III trial with results expected by early 2017 [12] . It is therefore likely that vaccines will have a growing role in the treatment of prostate cancer.
One obstacle to broad acceptance of sipuleucel-T is a lack of understanding of its mechanism of action and the development of companion biomarkers. Nonetheless, evidence of immunologic efficacy was seen in patients treated with sipuleucel-T, who demonstrated antigen spreading that was associated with improved outcomes [13] . Antigen spreading is a process whereby an activated immune response increases its breadth in vivo by targeting additional antigens beyond the primary target, in this case prostatic acid phosphatase. These additional targets come from tumor cells killed in an immunologically relevant manner and may become more diverse and clinically relevant over time. In a secondary analysis (n ¼ 142) in patients treated with sipuleucel-T, increased IgG responses to the secondary antigens PSA and LGALS3 (lectin, galactoside binding soluble 3) were associated with an OS advantage (P 0.05). These data suggest that patients who had the greatest breadth of immune response after treatment with sipuleucel-T had better clinical outcomes. Further evidence was provided by a neoadjuvant study of sipuleucel-T prior to radical prostatectomy [14 ] . These findings indicated that immune cells in the tumor microenvironment increased after treatment with sipuleucel-T, suggesting that immune cells activated by the vaccine subsequently migrated to the primary prostate cancer tumors in these patients. Together, these data provide compelling evidence of sipuleucel-T's ability to generate a meaningful antitumor immune response.
Another obstacle to broad acceptance of both these vaccines is the lack of consistent reports of PSA declines that could help to identify patients who are benefiting from this therapy. Although there are no data to support an intermediate biomarker of response, a retrospective analysis of sipuleucel-T suggests that patients with relatively lower baseline
KEY POINTS
Genitourinary cancers have been among the first to be responsive to immunotherapies, leading to FDA approval of the first anticancer therapeutic vaccine (for prostate cancer) and the use of PD-1/PD-L1 checkpoint inhibitors (for renal cell and bladder cancer).
Multiple studies are ongoing in genitourinary malignancies using immunotherapy in combination with other agents; some studies are using immunotherapies in earlier disease states to enhance the impact of these agents.
OS appears to be the best discriminator of efficacy for immunotherapies; predictive and prognostic biomarkers are urgently needed.
PSA levels had better treatment outcomes, perhaps providing some guidance in identifying the ideal candidates for treatment with vaccines [15] . A further clinical concern is that subsequent treatment with prednisone, a companion treatment of mCRPC therapies such as abiraterone and docetaxel, has potential immunosuppressive effects. However, data from a study combining abiraterone and prednisone with sipuleucel-T suggested no decrease in immune activation with concurrent use of prednisone and sipuleucel-T [16] . Furthermore, the initial phase III trial did not suggest a negative impact in patients who went on to be treated with docetaxel and prednisone after treatment with sipuleucel-T [10] . This growing body of data suggests substantial potential for therapeutic cancer vaccines in the treatment of mCRPC.
Preclinical studies set the stage for in-human trials of anti-CTLA-4 therapy in prostate cancer. Two important studies by Kwon et al. [17, 18] demonstrated the activity of anti-CTLA-4 therapy in a transgenic adenocarcinoma mouse prostate (TRAMP) cancer cell line (C57BL/six mouse model). Mice treated with anti-CTLA-4 mAb had a significant increase in tumor rejection compared with those treated with placebo, and this effect extended into a metastatic prostate cancer model. Multiple combination strategies have been explored in the preclinical setting and have shown statistical benefit, including T reg depletion prior to anti-CTLA-4 therapy, activation of the inducible costimulator pathway to enhance CTLA-4 blockade, and OX40 agonism combined with CTLA-4 blockade [19] [20] [21] .
Building on available preclinical data, several phase I/II hypothesis-generating trials have suggested the clinical utility of ipilimumab in the treatment of prostate cancer. In phase I, dose-escalation studies combining ipilimumab with the tumor cell vaccine GVAX (Cell Genesys Inc., San Francisco, California, USA) or PSA-TRICOM, PSA declines of more than 50% from baseline were seen in a minority of mCRPC patients [22, 23] . A phase Ib study of mCRPC patients treated with ipilimumab plus GM-CSF also demonstrated PSA response. Low pretreatment levels of surface PD-1 on effector T cells were correlated with improved OS. In a separate analysis, responders (defined as >50% PSA decline from baseline) were shown to generate antibody responses to a higher number of antigens than were nonresponders [24] [25] [26] . Ipilimumab was combined with palliative radiation (XRT) in a phase I/II study. mCRPC patients were treated in a doseescalation method with ipilimumab AE single-dose (8 Gy) XRT to bone metastases. Among patients treated with the highest dose of ipilimumab (10 mg/kg) AE XRT, 16% demonstrated PSA declines of more than 50% from baseline [27] . Although response rates were seen in these trials, they were generally low. Further optimizing timing and dosing of checkpoint inhibition in combination with alternative therapies, as well as defining predictors of response to therapy, requires further study.
A phase III, randomized, double-blinded, multicenter trial evaluated mCRPC patients with at least one bone metastasis amenable to XRT who had progressed on docetaxel. Patients were randomized to receive either bone-directed palliative radiation (XRT; single dose of 8 Gy) followed by ipilimumab 10 mg/kg or placebo. Median OS was 11.2 months in the ipilimumab group and 10.0 months in the placebo group (HR 0.85, 95% confidence interval 0.72-1.00; P ¼ 0.053), initially suggesting no clinical benefit from ipilimumab therapy. However, a crossover of the Kaplan-Meier curve was noted at 7-8 months, and on further analysis, the proportional hazard assumption was violated. Modeling showed that the HR decreased over time; after 12 months, the HR was 0.60 (95% confidence interval 0.43-0.86), suggesting a late benefit from ipilimumab therapy. Also of interest, post hoc analysis showed possible benefit in patients with pretreatment alkaline phosphatase less than 1.5 times the upper limit of normal, hemoglobin more than 11 g/dl, and no visceral metastasis [28] . Updated OS results at 3 years showed maintained results, as in the primary analysis, as well as a 3-year OS of 12% in the ipilimumab group vs. 6% in the placebo group [29] . Although the primary endpoint was not met in this phase III trial, questions remain concerning the choice of ipilimumab and XRT dose and sequence of therapy, as well as the inclusion of patients with visceral metastatic disease and prior treatment with chemotherapy. A phase III trial for which results are not yet available included treatment-naïve patients with no visceral metastatic disease and may help answer the questions generated by the previously discussed trial (Table 1) .
Recent studies have suggested limited antitumor immune infiltrates in prostate cancer with minimal associated PD-L1 expression [30] . This may explain the lack of objective response rate (ORR) seen to date with agents targeting PD-1 or PD-L1 in prostate cancer [31] . A recent phase II trial showed dramatic differential in response to anti-PD-1 therapy based on mismatch repair proficiency or deficiency. Mismatch repair mutation status is known to be important for the management of colorectal cancer, but this study suggested its use as a biomarker of response to checkpoint inhibition in the treatment of a range of solid malignancies. Mismatch repair deficiency may allow for increased burden of somatic mutations, leading to generation of tumorassociated antigens that are then targeted by a checkpoint inhibitor-generated immune response [32] . An analysis of prostate tumors has shown that up to 22% of tested samples had mutations in DNA repair/ recombination genes, including MSH2 and MSH6, suggesting that mismatch repair could play a role in response to checkpoint inhibition in genitourinary malignancies [33] . In addition, there are ongoing studies combining vaccines with agents targeting this pathway to see if this combination approach can provide the underlying immune response (with vaccines) whose activity can be enhanced by blocking PD-1 or PD-L1 [34] .
RENAL CELL CARCINOMA
Renal cell carcinoma (RCC) is considered to be immunotherapy-responsive. Anti-PD-1 therapy in the form of nivolumab was recently FDAapproved for treatment of advanced RCC based on a phase III trial demonstrating significant OS benefit [35 && ]. A recently published study randomized advanced RCC patients who had one or two lines of prior antiangiogenic therapy to treatment with nivolumab (n ¼ 410) or everolimus (n ¼ 411). Although progression-free survival was similar between the groups, the primary endpoint of OS favored nivolumab, with a 27% reduction in the risk of death (P ¼ 0.002) [35 && ]. Furthermore, those Despite the success of alternative immune checkpoint targets, CTLA-4 blockade monotherapy for the treatment of RCC has not been definitively examined in a phase III trial. In a mouse model of RCC, CTLA-4 blockade significantly inhibited tumor growth, and available phase I and II trial data suggest RCC response to monotherapy [36] [37] [38] . In a safety study, 61 patients with RCC were treated with ipilimumab monotherapy at doses of either 3 mg/kg followed by 1 or 3 mg/kg stable dosing. Patients who developed enterocolitis on treatment were found to have an ORR of 35 vs. 2% for patients who did not develop enterocolitis [37] . The meaning of this association is unclear. In a phase II trial, 40 patients with advanced RCC who had progressed on IL-2 therapy or were not eligible for IL-2 were treated with ipilimumab at 3 mg/kg. Based on Response Evaluation Criteria in Solid Tumors, an ORR of 12.5% was shown in this cohort, as was an association between immune-related adverse events and response to therapy [38] . Tremelimumab (MedImmune, Gaithersburg, Maryland, USA), a humanized antibody against CTLA-4, was found to have dose-limiting toxicities in combination with sunitinib in a phase I trial in metastatic RCC, limiting further study [39] . Continued study of checkpoint inhibition for RCC is now focusing on combination therapy (Table 1) .
BLADDER CANCER
An expansion cohort of atezolizumab (IgG1 anti-PD-L1 mAb) in advanced urothelial cancer suggested surprising activity in this cancer that has seen no major advances in 30 years. Sixty-eight patients received atezolizumab, 67 of whom were evaluable for efficacy. About 25% of patients had an objective response, and 13/30 (43%) had PD-L1 IHC scores of 2þ or 3þ. This treatment was well tolerated, with 4.4% of patients having grade 3 or greater adverse events. This led to a larger single-arm phase II study of 310 patients who had progressed during or following a platinum-based therapy, with ORR as the primary endpoint [40 && ]. The objective response was 15% overall and 26% in those tumors with PD-L1 on at least 5% of tumor-infiltrating immune cells (n ¼ 100). This led to FDA approval in May 2016, and a confirmatory randomized phase III study is underway. There are also encouraging data from pembrolizumab with an ORR of 25% (7/28 patients), avelumab (an IgG1 anti-PD-L1 antibody fully capable of antibody-dependent cell-mediated cytotoxicity; EMD Serono, Billerica, MA) with 8/44 patients having a response (18%), and 6/12 patients with at least 5% of tumor cells expressing PD-L1 having a response [41] . This has led to multiple ongoing studies with PD-1/PD-L1-targeting agents either alone or in combination with other agents in various stages of urothelial cancer, as recently reviewed [42, 43] .
FUTURE DIRECTIONS
Despite recent advances in immune checkpoint inhibition, the benefits are still limited to a minority of unselected patients (often <20%) who likely have a pre-existing immune response that can be unconstrained by immune checkpoint inhibition [44, 45] . A primary focus of future studies should be to evaluate strategies that enhance T-cell infiltration of the tumor microenvironment, thereby providing greater benefit to a broader population of cancer patients. Proof of concept comes from a neoadjuvant study in prostate cancer where sipuleucel-T demonstrated its ability to mobilize T cells to the tumor microenvironment when administered prior to radical prostatectomy [10,14 & ]. In this manner, subsequent combination studies with checkpoint inhibitors could capitalize on this augmented local immune response. Future studies will investigate another vaccine, Prostvac, in combination with ipilimumab and nivolumab (anti-PD-1) in the neoadjuvant setting in prostate cancer.
Similar principles underlie a current study investigating another anti-PD-1 antibody (pembrolizumab) in patients with high-risk but localized bladder cancer who have already been treated with bacillus Calmette-Guerin (BCG) (NCT02625961). It is likely that BCG's clinical benefit is based on nonspecific inflammation of the bladder that results in increased immune cell infiltration, thereby potentiating an antitumor immune response [46] . In some patients where PD-1/PD-L1 interactions may inhibit benefit from BCG alone, concurrent or, as in this trial, subsequent PD-1/PD-L1 inhibition may potentiate improved clinical outcomes.
Another focus of future trials will likely be the deployment of multiple immunotherapies as part of a therapeutic immunologic platform. A previous study combined the vaccine Prostvac with ipilimumab, resulting in improved OS (37.2 months in patients treated with 10 mg/kg ipilimumab; 31.3 months in all doses) relative to previous studies with Prostvac alone [47] . A phase I study (NCT02616185) is combining a prostate cancer vaccine with locally administered anti-CTLA-4 therapy (to maximize immune activation with the vaccine but minimize toxicity), PD-1 inhibition, and sunitinib (at a low dose with intent to deplete T regs [48] ). Although results with anti-PD-1/PD-L1 in prostate cancer have been disappointing, trials like this aim to optimize immune mobilization with a vaccine and local anti-CTLA-4 therapy in a receptive immune environment (depleted of T regs ), thereby potentiating the benefits of PD-1 inhibition within the tumor microenvironment.
Additional studies will capitalize on the growing understanding of how cytotoxic therapies or radiation may immunologically modulate tumors, enabling immune recognition and immune-mediated tumor cell killing [49] . This has been demonstrated in preliminary studies with radiation as well as chemotherapy [50, 51] . A previous trial compared the radiopharmaceutical samarium 153 with Prostvac to samarium 153 alone [52] . The results of the study suggested a substantial improvement in time to progression (3.7 vs. 1.7 months; P ¼ 0.03) as well as PSA responses in patients who had received the combination. The advent of an a-emitting radiopharmaceutical with less toxicity (radium 223) has led to studies combining that agent with sipuleucel-T (NCT02463799). In addition, an ongoing trial is evaluating Prostvac in combination with docetaxel in patients with newly diagnosed metastatic castration-sensitive prostate cancer (NCT02649855).
CONCLUSION
The use of immune checkpoint therapy for the treatment of genitourinary malignancies is an exciting area of active research. Available trials demonstrate checkpoint inhibitor efficacy in both RCC and bladder cancer. However, trials in prostate cancer have not yet shown clinical benefit. The reasons behind this are likely to be multifactorial and include host and tumor factors as well as timing and dosing of checkpoint inhibitor therapy. The combination of checkpoint inhibitor therapy with standard-of-care therapies and alternative immunotherapies is another area of active research that may improve ORRs. Despite evidence of long-term response to checkpoint blockade, relatively low ORRs are consistently seen in clinical trials evaluating treatment effect in genitourinary malignancies. Biomarker development is needed to inform selection of patients who will benefit most from this arm of cancer immunotherapy. However, patient selection is not enough. Ultimately, the goal is to achieve clinical benefit in a large majority of patients with genitourinary malignancies. This will only be achieved through continued exploration of cancer immunotherapy mechanisms of action.
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